US2022073589A1PendingUtilityA1

GPR156 Variants And Uses Thereof

70
Assignee: REGENERON PHARMAPriority: Jul 28, 2016Filed: Sep 23, 2021Published: Mar 10, 2022
Est. expiryJul 28, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Claudia Gonzaga-Jauregui
C07K 14/705C12Q 1/6883C12Q 2600/156A61P 25/24C07K 14/70571A61K 33/00
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure provides nucleic acids, including cDNA, comprising alterations that encode aspartic acid at a position corresponding to position 533 of the human G protein-coupled receptor 156 protein (GPR156). The disclosure also provides isolated and recombinant human GPR156 protein variants that comprise an aspartic acid at a position corresponding to position 533. The change to aspartic acid, and the gene encoding this change, associate with unipolar depression. The disclosure also provides methods for determining whether a subject has or has a risk of developing unipolar depression, based on the identification of such alterations in the gene (DNA or RNA) encoding GPR156.

Claims

exact text as granted — not AI-modified
1 - 28 . (canceled) 
     
     
         29 . A method for treating depression in a human, the method comprising administering an antidepressant to the human, wherein the human has one or more symptoms of depression, and wherein the human has an alteration in a nucleic acid molecule encoding a GPR156 protein, wherein the alteration encodes an aspartic acid at a position corresponding to position 533 in the GPR156 protein according to SEQ ID NO:4. 
     
     
         30 . The method according to  claim 29 , wherein the antidepressant is a selective serotonin reuptake inhibitor. 
     
     
         31 . The method according to  claim 29 , wherein the antidepressant is a serotonin-norepinephrine reuptake inhibitor. 
     
     
         32 . The method according to  claim 29 , wherein the antidepressant is a norepinephrine reuptake inhibitor. 
     
     
         33 . The method according to  claim 29 , wherein the antidepressant is lithium. 
     
     
         34 . The method according to  claim 29 , wherein the antidepressant is a serotonin modulator and stimulator (SMS). 
     
     
         35 . The method according to  claim 29 , wherein the antidepressant is a serotonin antagonist and reuptake inhibitor (SARI). 
     
     
         36 . The method according to  claim 29 , wherein the antidepressant is a tricyclic antidepressant (TCA). 
     
     
         37 . The method according to  claim 29 , wherein the antidepressant is a tetracyclic antidepressant (TeCA). 
     
     
         38 . The method according to  claim 29 , wherein the antidepressant is a monoamine oxidase inhibitor (MAOI). 
     
     
         39 . The method according to  claim 29 , wherein the antidepressant is an atypical antipsychotic. 
     
     
         40 . The method according to  claim 29 , wherein the antidepressant is agomelatine, bifemelane, bupropion, ketamine, tandospirone, or teniloxazine. 
     
     
         41 . The method according to  claim 29 , wherein the depression is unipolar depression. 
     
     
         42 . A method for treating an anxiety disorder in a human, the method comprising administering an antidepressant to the human, wherein the human has one or more symptoms of an anxiety disorder, and wherein the human has an alteration in a nucleic acid molecule encoding a GPR156 protein, wherein the alteration encodes an aspartic acid at a position corresponding to position 533 in the GPR156 protein according to SEQ ID NO:4. 
     
     
         43 . The method according to  claim 42 , wherein the antidepressant is a selective serotonin reuptake inhibitor. 
     
     
         44 . The method according to  claim 42 , wherein the antidepressant is a serotonin-norepinephrine reuptake inhibitor. 
     
     
         45 . The method according to  claim 42 , wherein the antidepressant is a norepinephrine reuptake inhibitor. 
     
     
         46 . The method according to  claim 42 , wherein the antidepressant is lithium. 
     
     
         47 . The method according to  claim 42 , wherein the antidepressant is a serotonin modulator and stimulator (SMS). 
     
     
         48 . The method according to  claim 42 , wherein the antidepressant is a serotonin antagonist and reuptake inhibitor (SARI). 
     
     
         49 . The method according to  claim 42 , wherein the antidepressant is a tricyclic antidepressant (TCA). 
     
     
         50 . The method according to  claim 42 , wherein the antidepressant is a tetracyclic antidepressant (TeCA). 
     
     
         51 . The method according to  claim 42 , wherein the antidepressant is a monoamine oxidase inhibitor (MAOI). 
     
     
         52 . The method according to  claim 42 , wherein the antidepressant is an atypical antipsychotic. 
     
     
         53 . The method according to  claim 42 , wherein the antidepressant is agomelatine, bifemelane, bupropion, ketamine, tandospirone, or teniloxazine. 
     
     
         54 . The method according to  claim 42 , wherein the anxiety disorder is clinical neuropsychiatric anxiety disorder.

Join the waitlist — get patent alerts

Track US2022073589A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.